Skip to Content

Brentuximab Dosage

Applies to the following strength(s): 50 mg

The information at is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Lymphoma

Initial dose: 1.8 mg/kg IV over 30 minutes every 3 weeks
Maximum dose: 180 mg

-Administer as an IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.
-For classical HL post-auto-HSCT consolidation treatment, treatment should be initiated within 4 to 6 weeks post-auto-HSCT or upon recovery from auto-HSCT. These patients should continue treatment until a maximum of 16 cycles, disease progression, or unacceptable toxicity.

-Classical HL after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates
-For the treatment of patients with classical HL at high risk of relapse or progression as post-auto-HSCT consolidation
-For treatment of patients with systemic anaplastic large cell lymphoma sALCL after failure of at least one prior multi-agent chemotherapy regimen

Renal Dose Adjustments

-CrCl greater than 50 to 80 mL/min AND CrCl 30 to 50 mL/min: 1.8 mg/kg up to 180 mg IV over 30 minutes
-CrCl less than 30 mL/min: Avoid use

Liver Dose Adjustments

-Mild hepatic impairment (Child-Pugh A): 1.2 mg/kg up to 120 mg IV over 30 minutes
-Moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment: Avoid use

Dose Adjustments

Peripheral Neuropathy:
-For new or worsening Grade 2 or 3 neuropathy, dosing should be held until neuropathy improves to Grade 1 or baseline and then restarted at 1.2 mg/kg IV over 30 minutes.
-For Grade 4 peripheral neuropathy therapy should be discontinued.

-The dose should be held for Grade 3 or 4 neutropenia until resolution to baseline or Grade 2 or lower. Consider G-CSF prophylaxis for subsequent cycles in patients who experience Grade 3 or 4 neutropenia in the previous cycle.
-In patients with recurrent Grade 4 neutropenia despite the use of G-CSF prophylaxis, consider discontinuation or dose reduction of 1.2 mg/kg IV over 30 minutes.


Progressive Multifocal Leukoencephalopathy (PML): John Cunningham virus (JCV) infection resulting in PML and death has been reported with this drug. First onset of symptoms occurred at various times from initiation of therapy, with some cases occurring within 3 months of initial exposure. In addition to therapy with this drug, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-This drug should be administered under the supervision of a physician experienced in the use of anti-cancer agents.
-Proper procedures for handling and disposal of anticancer drugs should be followed.

Reconstitution/preparation/storage advice:
-Refer to the manufacturer product information.